Improve your health

Two studies presented today at the 8th International Forum on Mood and Anxiety Disorders (IFMAD) in Vienna demonstrated that once-daily SEROQUEL XRTM (quetiapine fumarate extended release tablets) provided significant symptom relief for elderly patients (>65 years of age) with major depressive disorder (MDD) and generalised anxiety disorder (GAD). In both 9-week monotherapy studies - one in MDD (Sapphire)1 and the other in GAD (Chromium)2 - symptoms had improved significantly within one week of quetiapine XR treatment. Further new quetiapine XR data presented at IFMAD included an analysis of patients with anxious depression3 and results from the Amber study4 in MDD.
"Major depressive disorder and generalised anxiety disorder are two closely related conditions that can be difficult to treat, particularly in elderly people," said Professor Stuart Montgomery, Imperial College School of Medicine, London. "In these two studies with elderly patients, quetiapine XR worked quickly to relieve depression and anxiety symptoms within a week, and symptoms continued to improve until the end of the studies. These results are consistent with the positive results previously reported from other studies conducted with quetiapine XR in MDD and GAD in non-elderly adults."
The Sapphire (Study 14) and Chromium (Study 15) studies were double-blind, placebo-controlled trials that randomised elderly patients to receive flexible dose quetiapine XR monotherapy (50-300 mg/day) or placebo. The Sapphire study included 388 elderly MDD patients with a mean age of 71.3 years. Generic propecia pills no prescription After 9 weeks of treatment with quetiapine XR (mean dose 159.9 mg/day), Montgomery-?